Aaron J. Sorrin

Aaron J. Sorrin

University of Maryland

H-index: 6

North America-United States

About Aaron J. Sorrin

Aaron J. Sorrin, With an exceptional h-index of 6 and a recent h-index of 6 (since 2020), a distinguished researcher at University of Maryland,

His recent articles reflect a diverse array of research interests and contributions to the field:

Co-Packaged PARP inhibitor and photosensitizer for targeted photo-chemotherapy of 3D ovarian cancer spheroids

The role of fluid shear stress in regulating photoimmunotherapy efficacy and immunogenic cell death (Conference Presentation)

Photoimmunotherapy-Based Combination Regimens and Drug Delivery Systems for Ovarian Cancer Treatment

Fluorescence-guided photoimmunotherapy using targeted nanotechnology and ML7710 to manage peritoneal carcinomatosis

Transient fluid flow improves photoimmunoconjugate delivery and photoimmunotherapy efficacy

Fluorescence-guided, targeted photochemotherapy of peritoneal carcinomatosis

Photodynamic therapy-based combination regimen with EP4 inhibitors attenuates metastatic behavior in ovarian cancer

Evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy

Aaron J. Sorrin Information

University

University of Maryland

Position

___

Citations(all)

352

Citations(since 2020)

351

Cited By

43

hIndex(all)

6

hIndex(since 2020)

6

i10Index(all)

5

i10Index(since 2020)

5

Email

University Profile Page

University of Maryland

Top articles of Aaron J. Sorrin

Co-Packaged PARP inhibitor and photosensitizer for targeted photo-chemotherapy of 3D ovarian cancer spheroids

Authors

Aaron Sorrin,Anika Dasgupta,Kathryn McNaughton,Carla Arnau Del Valle,Keri Zhou,Cindy Liu,Dana M Roque,Huang Chiao Huang

Journal

Cell & Bioscience

Published Date

2024/2/6

BackgroundWithin the last decade, poly(ADP-ribose) polymerase inhibitors (PARPi) have emerged in the clinic as an effective treatment for numerous malignancies. Preclinical data have demonstrated powerful combination effects of PARPi paired with photodynamic therapy (PDT), which involves light-activation of specialized dyes (photosensitizers) to stimulate cancer cell death through reactive oxygen species generation.ResultsIn this report, the most potent clinical PARP inhibitor, talazoparib, is loaded into the core of a polymeric nanoparticle (NP-Tal), which is interfaced with antibody-photosensitizer conjugates (photoimmunoconjugates, PICs) to form PIC-NP-Tal. In parallel, a new 3D fluorescent coculture model is developed using the parental OVCAR-8-DsRed2 and the chemo-resistant subline, NCI/ADR-RES-EGFP. This model enables quantification of trends in the evolutionary dynamics of acquired …

The role of fluid shear stress in regulating photoimmunotherapy efficacy and immunogenic cell death (Conference Presentation)

Authors

Aaron Sorrin,Keri Zhou,Katherine May,Cindy Liu,Barry J Liang,Dana M Roque,Huang Chiao Huang

Published Date

2023/3/14

Photoimmunotherapy employs antibody-photosensitizer constructs (photoimmunoconjugates) for targeted cancer ablation through the generation of reactive oxygen species. While this approach enhances cancer cell specificity, it sacrifices cellular uptake. This study addresses this limitation through two strategies with an emphasis on anti-cancer immunogenicity: 1) utilizing fluid shear stress to mediate delivery, and 2) leveraging nanoengineering approaches to maximize photoimmunoconjugate payload. Results reveal that fluid shear stress promotes photosensitizer delivery and anti-tumor immune response while modulating subcellular localization. By shedding light on improved delivery strategies and formulations, this study generates important implications for the clinical implementation of photoimmunotherapy.

Photoimmunotherapy-Based Combination Regimens and Drug Delivery Systems for Ovarian Cancer Treatment

Authors

Aaron Sorrin

Published Date

2023

Ovarian cancer is among the deadliest gynecologic malignancies, accounting for over 13,000 deaths and nearly 20,000 new cases each year in the United States alone. The lethality of this disease results from several fundamental challenges, including diagnosis at advanced stages, development of resistance to standard-of-care chemotherapies, and extensive metastasis throughout the peritoneal cavity. Photodynamic therapy (PDT) is a promising treatment modality which enables spatiotemporally controlled cancer ablation upon light-activation of specialized drugs (photosensitizers). Clinical studies have demonstrated the feasibility and safety of PDT for women with peritoneally disseminated ovarian cancer, though treatment outcomes were limited by off-target toxicities and the heterogenous cellular uptake of photosensitizer. The use of antibody-conjugated photosensitizers (photoimmunoconjugates) has the potential to overcome these prior limitations, making the targeted version of PDT (photoimmunotherapy, PIT) a valuable tool for ovarian cancer treatment. The overarching objective of this dissertation is to develop PIT-based strategies for ovarian cancer management through three complimentary goals: 1) overcome metastatic behaviors in ovarian cancer using PIT-based combination therapies; 2) bolster photosensitizer drug delivery using a clinically-relevant, fluid flow-based drug delivery approach; and 3) enhance cytotoxic effects of PIT through developing a new nanocomplex for photochemotherapy. This work establishes novel PIT-based combination treatments that incorporate clinically relevant therapies, including prostaglandin E2 …

Fluorescence-guided photoimmunotherapy using targeted nanotechnology and ML7710 to manage peritoneal carcinomatosis

Authors

Barry J Liang,Sumiao Pang,Robert Perttila,Chen-Hua Ma,Payal Srivastava,Brandon Gaitan,Aaron J Sorrin,Nada Fadul,Idrisa Rahman,Zoe Yl o¨ niemi,Dana M Roque,Tayyaba Hasan,Petteri Uusimaa,Huang-Chiao Huang

Journal

Science Advances

Published Date

2023/9/6

Fluorescence-guided intervention can bolster standard therapies by detecting and treating microscopic tumors before lethal recurrence. Tremendous progress in photoimmunotherapy and nanotechnology has been made to treat metastasis. However, many are lost in translation due to heterogeneous treatment effects. Here, we integrate three technological advances in targeted photo-activable multi-agent liposome (TPMAL), fluorescence-guided intervention, and laser endoscopy (ML7710) to improve photoimmunotherapy. TPMAL consists of a nanoliposome chemotherapy labeled with fluorophores for tracking and photosensitizer immunoconjugates for photoimmunotherapy. ML7710 is connected to Modulight Cloud to capture and analyze multispectral emission from TPMAL for fluorescence-guided drug delivery (FGDD) and fluorescence-guided light dosimetry (FGLD) in peritoneal carcinomatosis mouse models …

Transient fluid flow improves photoimmunoconjugate delivery and photoimmunotherapy efficacy

Authors

Aaron J Sorrin,Keri Zhou,Katherine May,Cindy Liu,Kathryn McNaughton,Idrisa Rahman,Barry J Liang,Imran Rizvi,Dana M Roque,Huang-Chiao Huang

Journal

Iscience

Published Date

2023/8/18

Circulating drugs in the peritoneal cavity is an effective strategy for advanced ovarian cancer treatment. Photoimmunotherapy, an emerging modality with potential for the treatment of ovarian cancer, involves near-infrared light activation of antibody-photosensitizer conjugates (photoimmunoconjugates) to generate cytotoxic reactive oxygen species. Here, a microfluidic cell culture model is used to study how fluid flow-induced shear stress affects photoimmunoconjugate delivery to ovarian cancer cells. Photoimmunoconjugates are composed of the antibody, cetuximab, conjugated to the photosensitizer, and benzoporphyrin derivative. Longitudinal tracking of photoimmunoconjugate treatment under flow conditions reveals enhancements in subcellular photosensitizer accumulation. Compared to static conditions, fluid flow-induced shear stress at 0.5 and 1 dyn/cm2 doubled the cellular delivery of …

Fluorescence-guided, targeted photochemotherapy of peritoneal carcinomatosis

Authors

Barry J Liang,Robert Perttilä,Sumiao Pang,Chen-Hua Ma,Payal Srivastava,Brandon Gaitan,Aaron J Sorrin,Zoe Ylöniemi,Dana Roque,Tayyaba Hasan,Petteri Uusimaa,Huang-Chiao Huang

Published Date

2023/3/17

This conference presentation was prepared for the Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XXXI conference at SPIE BiOS, SPIE Photonics West 2023.

Photodynamic therapy-based combination regimen with EP4 inhibitors attenuates metastatic behavior in ovarian cancer

Authors

Aaron Sorrin,Jocelyn Reader,Cindy Liu,Julia Cicalo,Danial Najafali,Dana Roque,Huang Chiao Huang

Published Date

2021/3/5

Ovarian cancer typically spreads throughout the peritoneal cavity, and despite standard of care treatments (surgical debulking and chemotherapy), the five-year relative survival rate remains below 50%. The use of antibody-photosensitizer conjugates (photoimmunotherapy) has emerged as a promising modality to achieve targeted photosensitizer delivery to ovarian cancer cells. In this study, we investigate epithelial growth factor (EGFR)-targeted PIT coupled with inhibition of prostaglandin E2 receptor 4 (EP4), a G-coupled-receptor that contributes to cancer progression and intracellularly transactivates EGFR. This potent triple combination significantly attenuates the metastatic behavior of ovarian cancer cells through simultaneously inducing photochemical damage and modulating protein expression.

Evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy

Authors

Yan Baglo,Aaron J Sorrin,Xiaocong Pu,Cindy Liu,Jocelyn Reader,Dana M Roque,Huang-Chiao Huang

Journal

Translational Oncology

Published Date

2021/11/1

P-glycoprotein (P-gp) is an adenosine triphosphate (ATP)-dependent drug efflux protein commonly associated with multidrug resistance in cancer chemotherapy. In this report, we used a dual-fluorescent co-culture model to study the population dynamics of the drug sensitive human ovarian cancer cell line (OVCAR-8-DsRed2) and its resistant subline that overexpresses P-gp (NCI/ADR-RES-EGFP) during the course of a photodynamic therapy (PDT)-olaparib combination regimen. Without treatment, OVCAR-8-DsRed2 cells grew more rapidly than the NCI/ADR-RES-EGFP cells. Olaparib treatment reduced the total number of cancer cells by 70±4% but selected for the resistant NCI/ADR-RES-EGFP population since olaparib is an efflux substrate for the P-gp pump. This study used the FDA-approved benzoporphyrin derivative (BPD) photosensitizer or its lipidated formulation ((16:0)LysoPC-BPD) to kill OVCAR-8 cells …

Photodynamic priming improves the anti-migratory activity of prostaglandin E receptor 4 antagonist in cancer cells in vitro

Authors

Aaron J Sorrin,Cindy Liu,Julia Cicalo,Jocelyn Reader,Daniel Najafali,Yuji Zhang,Dana M Roque,Huang-Chiao Huang

Journal

Cancers

Published Date

2021/10/20

Simple Summary Photodynamic priming is an emerging strategy that leverages subtherapeutic photochemistry for therapeutic benefits, often used as part of combination regimens. Our study aimed to couple photodynamically priming with antagonism of the prostaglandin E receptor 4, a therapeutic target linked to cancer-associated migration, invasion, angiogenesis, and immune evasion. Photodynamic priming and antagonism of the prostaglandin E receptor 4 independently attenuated OVCAR-5 ovarian cancer cell migration in a gap closure model, though their combination induced the most significant reductions. More potent combination effects were revealed when invasiveness was characterized using a transwell invasion model with CAOV3 ovarian cancer cells. Immunoblotting identified the epithelial growth factor receptor, cAMP-response element binding protein, and extracellular signal-regulated kinase 1/2 as potential mediators of these combinational effects. This work provides new evidence of a novel and clinically relevant combination strategy to address metastatic behavior, a major challenge in the treatment of cancer. Abstract The combination of photodynamic agents and biological inhibitors is rapidly gaining attention for its promise and approval in treating advanced cancer. The activity of photodynamic treatment is mainly governed by the formation of reactive oxygen species upon light activation of photosensitizers. Exposure to reactive oxygen species above a threshold dose can induce cellular damage and cancer cell death, while the surviving cancer cells are “photodynamically primed”, or …

Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response

Authors

Brittany P Rickard,Christina Conrad,Aaron J Sorrin,Mustafa Kemal Ruhi,Jocelyn C Reader,Stephanie A Huang,Walfre Franco,Giuliano Scarcelli,William J Polacheck,Dana M Roque,Marcela G del Carmen,Huang-Chiao Huang,Utkan Demirci,Imran Rizvi

Published Date

2021/1

Simple Summary Accumulation of excess fluid in the abdomen typically indicates abnormal function or disease, such as cancer, in the underlying tissues. This accumulation of fluid, or ascites, occurs more frequently in patients with advanced-stage ovarian cancer than any other type of cancer. The presence of ascites indicates the poorest outcomes for patients with advanced stage ovarian cancer, but little is known about the reasons for these dismal outcomes. This review discusses the current understanding of ascites, starting with an overview of ovarian cancer and ascites, followed by a description of the tools used to analyze the components of ascites and how these components modulate ovarian cancer biology. A perspective on the mechanical effects of ascites and the impact of mechanical stress on treatment resistance is provided. Lastly, treatment options for ascites and opportunities to develop new therapeutic strategies to improve outcomes are discussed. Abstract Ascites refers to the abnormal accumulation of fluid in the peritoneum resulting from an underlying pathology, such as metastatic cancer. Among all cancers, advanced-stage epithelial ovarian cancer is most frequently associated with the production of malignant ascites and is the leading cause of death from gynecologic malignancies. Despite decades of evidence showing that the accumulation of peritoneal fluid portends the poorest outcomes for cancer patients, the role of malignant ascites in promoting metastasis and therapy resistance remains poorly understood. This review summarizes the current understanding of malignant ascites, with a …

Engineering gold nanoparticles for photothermal therapy, surgery, and imaging

Authors

Jillian Stabile,Daniel Najafali,Yahya Cheema,Collin T Inglut,Barry J Liang,Swapna Vaja,Aaron J Sorrin,Huang-Chiao Huang

Published Date

2020/1/1

Photothermal therapy (PTT) is an externally activated approach that generates heat to damage, repair, or modulate biological targets. Gold nanoparticles (GNPs) combined with PTT provide unique opportunities for biomedical applications, where light activation can trigger both direct heat-mediated cytotoxicity and the release of drug payloads from nanoparticles. The combination of PTT and other cancer therapies, based on interactive mechanisms that target multiple nonoverlapping growth and survival pathways, is key to improving treatment outcomes. With advances in the development of GNPs and miniaturized light delivery systems, PTT can now access diseases at hard-to-reach anatomical sites in our body. This section introduces engineering aspects interfacing PTT and GNPs, as well as their preclinical and clinical applications in therapy, surgery, and diagnosis.

Photoimmunoconjugate nanoparticle, mechanism-based therapy for intraperitoneal treatment of carcinomatosis

Authors

Dana Marie Roque,Aaron Sorrin,Jocelyn Reader,Huang-Chiao Huang

Journal

Gynecologic Oncology

Published Date

2020/10/1

Objective: Photoimmunoconjugate nanoparticles (PICNP) consist of antibody-bound photosensitizers conjugated to small molecule inhibitors or other cytotoxic agents as nanoparticles. Antibody targeting achieves specificity of delivery to cancer cells. The photosensitizer may then be activated by near-infrared light to selectively induce tumor destruction mediated by mitochondrial membrane destruction conferring a pro-apoptotic state that sensitizes the cells to the cargo. In this work, we develop a novel PICNP consisting of cetuximab (anti-epidermal growth factor receptor, EGFR), benzoporphyrin derivative (BPD), and inhibitors of EP4 (EP4i)—a modulator of inflammation and the cyclo-oxygenase (COX) pathway (Figure 1A). EGFR is known to be upregulated in 35%–70% of ovarian cancers, and we have previously shown strong EP4 expression by immunohistochemistry in approximately 64% of serous, 40% of …

Harnessing the potential synergistic interplay between photosensitizer dark toxicity and chemotherapy

Authors

Yan Baglo,Aaron J Sorrin,Barry J Liang,Huang‐Chiao Huang

Journal

Photochemistry and photobiology

Published Date

2020/5

The combination of photodynamic therapy and taxol‐ or platinum‐based chemotherapy (photochemotherapy) is an effective and promising cancer treatment. While the mechanisms of action of photochemotherapy are actively studied, relatively little is known about the cytotoxicity and molecular alterations induced by the combination of chemotherapy and photosensitizers without light activation in cancer cells. This study investigates the interplay between the photosensitizer benzoporphyrin derivative (BPD) without light activation and cisplatin or paclitaxel in two glioblastoma lines, U87 and U251. The combination effect of BPD and cisplatin in U87 cells is slightly synergistic (combination index, CI = 0.93), showing 1.8‐ to 2.6‐fold lower half‐maximal inhibitory concentrations (IC50) compared to those of individual drugs. In contrast, combining BPD and paclitaxel is slightly antagonistic (CI = 1.14) in U87 cells. In U251 …

Photodynamic therapy and the biophysics of the tumor microenvironment

Authors

Aaron J Sorrin,Mustafa Kemal Ruhi,Nathaniel A Ferlic,Vida Karimnia,William J Polacheck,Jonathan P Celli,Huang‐Chiao Huang,Imran Rizvi

Published Date

2020/3

Targeting the tumor microenvironment (TME) provides opportunities to modulate tumor physiology, enhance the delivery of therapeutic agents, impact immune response and overcome resistance. Photodynamic therapy (PDT) is a photochemistry‐based, nonthermal modality that produces reactive molecular species at the site of light activation and is in the clinic for nononcologic and oncologic applications. The unique mechanisms and exquisite spatiotemporal control inherent to PDT enable selective modulation or destruction of the TME and cancer cells. Mechanical stress plays an important role in tumor growth and survival, with increasing implications for therapy design and drug delivery, but remains understudied in the context of PDT and PDT‐based combinations. This review describes pharmacoengineering and bioengineering approaches in PDT to target cellular and noncellular components of the TME, as …

Immunological and toxicological considerations for the design of liposomes

Authors

Collin T Inglut,Aaron J Sorrin,Thilinie Kuruppu,Shruti Vig,Julia Cicalo,Haroon Ahmad,Huang-Chiao Huang

Published Date

2020/1/22

Liposomes hold great potential as gene and drug delivery vehicles due to their biocompatibility and modular properties, coupled with the major advantage of attenuating the risk of systemic toxicity from the encapsulated therapeutic agent. Decades of research have been dedicated to studying and optimizing liposomal formulations for a variety of medical applications, ranging from cancer therapeutics to analgesics. Some effort has also been made to elucidate the toxicities and immune responses that these drug formulations may elicit. Notably, intravenously injected liposomes can interact with plasma proteins, leading to opsonization, thereby altering the healthy cells they come into contact with during circulation and removal. Additionally, due to the pharmacokinetics of liposomes in circulation, drugs can end up sequestered in organs of the mononuclear phagocyte system, affecting liver and spleen function. Importantly, liposomal agents can also stimulate or suppress the immune system depending on their physiochemical properties, such as size, lipid composition, pegylation, and surface charge. Despite the surge in the clinical use of liposomal agents since 1995, there are still several drawbacks that limit their range of applications. This review presents a focused analysis of these limitations, with an emphasis on toxicity to healthy tissues and unfavorable immune responses, to shed light on key considerations that should be factored into the design and clinical use of liposomal formulations.

See List of Professors in Aaron J. Sorrin University(University of Maryland)

Aaron J. Sorrin FAQs

What is Aaron J. Sorrin's h-index at University of Maryland?

The h-index of Aaron J. Sorrin has been 6 since 2020 and 6 in total.

What are Aaron J. Sorrin's top articles?

The articles with the titles of

Co-Packaged PARP inhibitor and photosensitizer for targeted photo-chemotherapy of 3D ovarian cancer spheroids

The role of fluid shear stress in regulating photoimmunotherapy efficacy and immunogenic cell death (Conference Presentation)

Photoimmunotherapy-Based Combination Regimens and Drug Delivery Systems for Ovarian Cancer Treatment

Fluorescence-guided photoimmunotherapy using targeted nanotechnology and ML7710 to manage peritoneal carcinomatosis

Transient fluid flow improves photoimmunoconjugate delivery and photoimmunotherapy efficacy

Fluorescence-guided, targeted photochemotherapy of peritoneal carcinomatosis

Photodynamic therapy-based combination regimen with EP4 inhibitors attenuates metastatic behavior in ovarian cancer

Evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy

...

are the top articles of Aaron J. Sorrin at University of Maryland.

What is Aaron J. Sorrin's total number of citations?

Aaron J. Sorrin has 352 citations in total.

    academic-engine

    Useful Links